Home > Insider Trading > Filing (0001104659-21-110547)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1818382	Humacyte Inc.	HUMA	Biological Products, (No Disgnostic Substances) (2836)	851763759

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1878075	E Laura Niklason	2525 East North Carolina Highway 54 Durham NC 27713	President, Ceo And Director	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-08-26	1,148,240	$0.00	1,148,240	No	4	A	Direct
Common Stock	Acquisiton	2021-08-26	18,930,004	$0.00	18,930,004	No	4	A	Indirect	By Ayabudge LLC
Common Stock	Acquisiton	2021-08-26	1,522,500	$10.00	20,452,504	No	4	P	Indirect	By Ayabudge LLC

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	A	Indirect	By Ayabudge LLC
No	4	P	Indirect	By Ayabudge LLC

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options (right to buy)	Acquisiton	2021-08-26	262,596	$0.00	262,596	$1.19
Common Stock	Stock Options (right to buy)	Acquisiton	2021-08-26	13,129	$0.00	13,129	$2.56
Common Stock	Stock Options (right to buy)	Acquisiton	2021-08-26	157,558	$0.00	157,558	$2.56
Common Stock	Stock Options (right to buy)	Acquisiton	2021-08-26	262,596	$0.00	262,596	$3.44
Common Stock	Stock Options (right to buy)	Acquisiton	2021-08-26	131,298	$0.00	131,298	$6.54
Common Stock	Stock Options (right to buy)	Acquisiton	2021-08-26	1,312,984	$0.00	1,312,984	$10.28
Common Stock	Stock Options (right to buy)	Acquisiton	2021-08-26	1,575	$0.00	1,575	$10.28
Common Stock	Stock Options (right to buy)	Acquisiton	2021-08-26	13,129	$0.00	13,129	$2.56
Common Stock	Stock Options (right to buy)	Acquisiton	2021-08-26	17,068	$0.00	17,068	$6.54

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
262,596		2023-11-22	No	4	A	Direct
13,129		2025-09-01	No	4	A	Direct
157,558		2026-03-09	No	4	A	Direct
262,596		2026-09-14	No	4	A	Direct
131,298		2028-04-12	No	4	A	Direct
1,312,984	2021-11-09	2031-01-14	No	4	A	Direct
1,575	2021-12-14	2030-12-14	No	4	A	Direct
13,129		2025-09-01	No	4	A	Indirect
17,068		2028-04-12	No	4	A	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	810,161	Indirect	By Spouse

Footnotes

On August 26, 2021 , Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc.
Options are fully vested and exercisable.
As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc.
One-third of the option will vest on each of the three anniversaries after November 9, 2020.
Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant.